Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2011 1
2012 1
2013 1
2014 3
2016 1
2019 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R, Tibau A, Molto Valiente C, Šeruga B, Ocaña A, Amir E, Templeton AJ. Adam R, et al. PLoS One. 2022 Jun 10;17(6):e0268545. doi: 10.1371/journal.pone.0268545. eCollection 2022. PLoS One. 2022. PMID: 35687539 Free PMC article.
Substantial benefit for ESMO-MCBS, was defined as a grade A or B for (neo)adjuvant intent and 4 or 5 for palliative intent. For ASCO-VF and OLUtool clinical benefit was defined as score 45 and A or B, respectively. ...
Substantial benefit for ESMO-MCBS, was defined as a grade A or B for (neo)adjuvant intent and 4 or 5 for palliative intent. For ASCO- …
Management of small HER2 overexpressing tumours.
Templeton A, Ocaña A, Seruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Templeton A, et al. Breast Cancer Res Treat. 2012 Nov;136(1):289-93. doi: 10.1007/s10549-012-2236-9. Epub 2012 Sep 6. Breast Cancer Res Treat. 2012. PMID: 22956007
Little is known about the role of such adjuvant treatment in node-negative subcentimeter tumours ('small tumours', pT1a/b) because these patients were generally excluded from the pivotal trials. ...
Little is known about the role of such adjuvant treatment in node-negative subcentimeter tumours ('small tumours', pT1a/b) because th …
Cancer care workforce in Africa: perspectives from a global survey.
Vanderpuye V, Hammad N, Martei Y, Hopman WM, Fundytus A, Sullivan R, Seruga B, Lopes G, Sengar M, Brundage MD, Booth CM. Vanderpuye V, et al. Infect Agent Cancer. 2019 May 21;14:11. doi: 10.1186/s13027-019-0227-8. eCollection 2019. Infect Agent Cancer. 2019. PMID: 31139248 Free PMC article.
Variation in the bioactive compound content at three ripening stages of strawberry fruit.
Voća S, Zlabur JS, Dobričević N, Jakobek L, Seruga M, Galić A, Pliestić S. Voća S, et al. Molecules. 2014 Jul 17;19(7):10370-85. doi: 10.3390/molecules190710370. Molecules. 2014. PMID: 25036150 Free PMC article.
The results show a positive association between cultivar and harvest time on strawberry pulp color, with each of the color variables, a, b, a/b ratio, C, L and h values....
The results show a positive association between cultivar and harvest time on strawberry pulp color, with each of the color variables, a, …
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Amir E, et al. J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606435
RESULTS: For overall survival (OS), the pooled HR was 0.69 (95% CI, 0.59 to 0.81) for group A (six drugs, six trials); it was 0.78 (95% CI, 0.74 to 0.83) for group B (seven drugs, 14 trials); and it was 0.84 (95% CI, 0.79 to 0.90) for group C (eight drugs, 12 trials). For …
RESULTS: For overall survival (OS), the pooled HR was 0.69 (95% CI, 0.59 to 0.81) for group A (six drugs, six trials); it was 0.78 (95% CI, …
In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.
Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Nieto-Jiménez C, Templeton AJ, Seruga B, Pandiella A, Amir E. Ocaña A, et al. Oncotarget. 2016 Apr 19;7(16):22865-72. doi: 10.18632/oncotarget.8118. Oncotarget. 2016. PMID: 26992217 Free PMC article.
Expression of 9 of these genes (CDC28, CHK1, NIMA, Aurora kinase A, Aurora kinase B, BUB1, BUB1betaB, CDKN2A and TTK) was associated with worse PFS (HR:3.40, log rank p<0.001). ...
Expression of 9 of these genes (CDC28, CHK1, NIMA, Aurora kinase A, Aurora kinase B, BUB1, BUB1betaB, CDKN2A and TTK) was associated …
Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg).
Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, Georgopoulos S, Tepes B, Heluwaert F, Gasbarrini A, Rokkas T, Bordin D, Smith S, Lamy V, Caldas M, Resina E, Muñoz R, Cosme Á, Puig I, Megraud F, O'Morain C, Gisbert JP; The Hp-EuReg Investigators. Bujanda L, et al. Antibiotics (Basel). 2021 Sep 1;10(9):1058. doi: 10.3390/antibiotics10091058. Antibiotics (Basel). 2021. PMID: 34572640 Free PMC article.
11 results